{"id":1022527,"date":"2026-11-19T07:33:19","date_gmt":"2026-11-19T12:33:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/"},"modified":"2026-11-19T07:33:19","modified_gmt":"2026-11-19T12:33:19","slug":"tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium<\/b><\/p>\n<p><i>Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisions<\/i><\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTempus AI, Inc. (NASDAQ: TEM) today announced that 16 abstracts leveraging its diagnostic capabilities and extensive multimodal database will be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8\u201311 in San Antonio.<\/p>\n<p>\nIn addition, a late-breaking abstract will highlight how Tempus&#8217; multimodal oncology foundation model (oFM), trained on data from more than 1.6 million cancer patients, integrates longitudinal clinical and molecular data to identify differences in patient outcomes and potential treatment benefits in metastatic breast cancer.<\/p>\n<p>\nBreast cancer is increasingly understood as a collection of biologically distinct diseases, with treatment decisions shaped by differences in tumor biology, molecular characteristics and how cancers evolve over time. Across the studies being presented, Tempus and its research collaborators showcase how connecting molecular, clinical and real-world data can generate actionable insights into cancer biology, treatment response and patient risk.<\/p>\n<p>\n\u201cAs our understanding of breast cancer advances and treatment options expand, having the right information to guide care is more important than ever,\u201d said Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus. \u201cBy combining advanced molecular testing with our extensive multimodal database and AI, we are uncovering insights that go beyond conventional approaches to understanding cancer biology, treatment response and resistance. This research demonstrates the potential of our integrated platform to inform more personalized treatment decisions and advance cancer care.\u201d<\/p>\n<p>\nThe full list of accepted abstracts include (all times CST):<\/p>\n<p>\nDecember 9, 12:30 PM &#8211; 2:00 PM | Abstract Number: P1-5-27<br \/>\n<br \/><b>HER2 RNA outperforms IHC in predicting outcomes to T-DXd<\/b><\/p>\n<p>\nDecember 9, 12:30 PM &#8211; 2:00 PM | Abstract Number: 958<br \/>\n<br \/><b>Genomic and immunologic landscape of triple-negative breast cancer by age: A comprehensive analysis of over 3,000 patients<\/b><\/p>\n<p>\nDecember 9, 12:30 PM &#8211; 2:00 PM |<b \/>Abstract Number: 827<br \/>\n<br \/><b>Sequencing of PARP inhibitors and trastuzumab deruxtecan in BRCA1\/2\/PALB2-altered, HER2-negative metastatic breast cancer: A retrospective study from the nationwide de-identified Tempus database<\/b><\/p>\n<p>\nDecember 9, 12:30 PM &#8211; 2:00 PM | Abstract Number: 1650<br \/>\n<br \/><b>Distinct mutational and immunologic profiles in HR+\/HER2-negative early-onset breast cancer (eoBC): Results from a large clinico-genomic database<\/b><\/p>\n<p>\nDecember 9, 12:30 PM &#8211; 2:00 PM | Abstract Number: 3116<br \/>\n<br \/><b>SUZ12-low invasive lobular carcinoma defines a receptor-subtype-independent molecular subgroup: A real-world multimodal analysis<\/b><\/p>\n<p>\nDecember 9, 4:30 PM &#8211; 5:30 PM | Abstract # RF3-1<br \/>\n<br \/><b>Clinical validation of a multimodal model for frontline therapeutic selection in breast cancer<\/b><\/p>\n<p>\nDecember 9, 5:00 PM &#8211; 6:30 PM | Abstract number: 365<br \/>\n<br \/><b>Real-world detection, molecular characterization, and clinical implications of emerging ESR1 mutations (ESR1m) during first-line (1L) treatment of hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) metastatic breast cancer (mBC)<\/b><\/p>\n<p>\nDecember 10, 7:00 AM &#8211; 8:30 AM | Abstract Number: 2136<br \/>\n<br \/><b>Immune profile score (IPS) to stratify outcomes in patients with metastatic triple negative breast cancer (mTNBC) treated with immune checkpoint inhibitors (ICIs)<\/b><\/p>\n<p>\nDecember 10, 7:00 AM &#8211; 8:30 AM | Abstract Number: 683<br \/>\n<br \/><b>Trastuzumab deruxtecan (T-DXd) versus sacituzumab govitecan (SG) in HER2-low\/0 metastatic breast cancer (mBC) by HER2 status and Trop-2 expression<\/b><\/p>\n<p>\nDecember 10, 12:30 PM &#8211; 2:00 PM | Late Breaking Abstract Number: 3439<br \/>\n<br \/><b>Predicting outcomes and differential treatment benefit in post-CDK4\/6i HR+\/HER2- metastatic breast cancer using longitudinal EHR data and a multimodal oncology foundation model (oFM)<\/b><\/p>\n<p>\nDecember 10, 12:30 PM\u20132:00 PM | Abstract Number: 3020<br \/>\n<br \/><b>10 Years in the Making: Genetic Test Results in a Large Male Breast Cancer Cohort in an Evolving Genomic Landscape<\/b><\/p>\n<p>\nDecember 10, 12:30 PM\u20132:00 PM | Abstract Number: 3009<br \/>\n<br \/><b>Timing of breast cancer surveillance: Is the \u201c10-years earlier\u201d rule appropriate?<\/b><\/p>\n<p>\nDecember 10, 5:00 PM &#8211; 6:30 PM | Abstract Number: 1656<br \/>\n<br \/><b>Integrating psychiatric pharmacogenomics in breast cancer care: Provider perspectives and clinical utilization in patients with comorbid emotional distress<\/b><\/p>\n<p>\nDecember 10, 5:00 PM &#8211; 6:30 PM | Abstract Number: 382<br \/>\n<br \/><b>Real-world outcomes of metastatic invasive lobular carcinoma (mILC) vs. invasive ductal carcinoma (mIDC) treated with PI3K inhibitors<\/b><\/p>\n<p>\nDecember 11, 12:30 PM &#8211; 2:00 PM | Abstract Number: 1251<br \/>\n<br \/><b>Fragmentomics enables actionable breast cancer subtyping on a commercial liquid biopsy assay<\/b><\/p>\n<p>\nDecember 11, 12:30 PM &#8211; 2:00 PM | Abstract Number: 1522<br \/>\n<br \/><b>Whole-genome sequencing reveals distinctive chromosome 17 copy number and structural variant landscapes in breast cancer tissue samples<\/b><\/p>\n<p><b>About Tempus AI<br \/>\n<br \/><\/b>Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world\u2019s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before.<\/p>\n<p>\nFor more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tempus.com%2F&amp;esheet=54643709&amp;newsitemid=20261119739681&amp;lan=en-US&amp;anchor=tempus.com&amp;index=1&amp;md5=b276150196ef18690fda21318575315c\">tempus.com<\/a> and follow Tempus on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftempuslabs%2F&amp;esheet=54643709&amp;newsitemid=20261119739681&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=9682ed3a19d210206f9a868da34278f6\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Ftempus.ai&amp;esheet=54643709&amp;newsitemid=20261119739681&amp;lan=en-US&amp;anchor=Instagram&amp;index=3&amp;md5=c9ed1cca33c947526d02bdfc9d792bbd\">Instagram<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FTempusAI&amp;esheet=54643709&amp;newsitemid=20261119739681&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=57ba72080f3bd7be0e964a062604890c\">X<\/a>.<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus\u2019 industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus\u2019 research and publications; the contributions of Tempus\u2019 research and findings to the larger scientific community and the use of Tempus\u2019 products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoing to,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.<\/p>\n<p>\nYou should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus\u2019 business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus\u2019 financial performance; the ability to attract and retain customers and partners; managing Tempus\u2019 growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus\u2019 intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled \u201cRisk Factors\u201d in Tempus\u2019 Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261119739681\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261119739681\/en\/<\/a><\/span><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Kelli Manalli<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kelli.manalli@tempus.com\">kelli.manalli@tempus.com<\/a><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Kendra Webster<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kendra.webster@tempus.com\">kendra.webster@tempus.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Illinois Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Technology Genetics Other Health Biotechnology General Health Health Science Oncology Artificial Intelligence<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261119739681\/en\/566718\/3\/black_wordmark.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisions CHICAGO&#8211;(BUSINESS WIRE)&#8211; Tempus AI, Inc. (NASDAQ: TEM) today announced that 16 abstracts leveraging its diagnostic capabilities and extensive multimodal database will be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8\u201311 in San Antonio. In addition, a late-breaking abstract will highlight how Tempus&#8217; multimodal oncology foundation model (oFM), trained on data from more than 1.6 million cancer patients, integrates longitudinal clinical and molecular data to identify differences in patient outcomes and potential treatment benefits in metastatic breast cancer. Breast cancer is increasingly understood as a collection of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022527","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisions CHICAGO&#8211;(BUSINESS WIRE)&#8211; Tempus AI, Inc. (NASDAQ: TEM) today announced that 16 abstracts leveraging its diagnostic capabilities and extensive multimodal database will be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8\u201311 in San Antonio. In addition, a late-breaking abstract will highlight how Tempus&#8217; multimodal oncology foundation model (oFM), trained on data from more than 1.6 million cancer patients, integrates longitudinal clinical and molecular data to identify differences in patient outcomes and potential treatment benefits in metastatic breast cancer. Breast cancer is increasingly understood as a collection of &hellip; Continue reading &quot;Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T12:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium\",\"datePublished\":\"2026-11-19T12:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/\"},\"wordCount\":1261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/\",\"name\":\"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-19T12:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium - Market Newsdesk","og_description":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisions CHICAGO&#8211;(BUSINESS WIRE)&#8211; Tempus AI, Inc. (NASDAQ: TEM) today announced that 16 abstracts leveraging its diagnostic capabilities and extensive multimodal database will be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8\u201311 in San Antonio. In addition, a late-breaking abstract will highlight how Tempus&#8217; multimodal oncology foundation model (oFM), trained on data from more than 1.6 million cancer patients, integrates longitudinal clinical and molecular data to identify differences in patient outcomes and potential treatment benefits in metastatic breast cancer. Breast cancer is increasingly understood as a collection of &hellip; Continue reading \"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-19T12:33:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium","datePublished":"2026-11-19T12:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/"},"wordCount":1261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/","name":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-19T12:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119739681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-to-present-16-abstracts-at-the-2026-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022527"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}